Outlook Therapeutics has seen its analyst consensus price target increase from $1.90 to $2.80, driven by promising Phase III trial results for its eye disease drug ONS-5010 and strategic partnerships. The company is expected to beat upcoming quarterly earnings estimates, which could further boost investor confidence. Despite some cautious views, overall sentiment reflects growing optimism about the company's future performance in the biopharmaceutical sector.
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Rothschild & Co Redburn raised Microsoft's price target from $400 to $440 following strong fiscal 2026 results, with revenue up 18% to $331.8 billion and net income rising 31% to $133.7 billion, driven by cloud and AI demand. Despite the target hike,...
Accenture's stock fell 4.73% to $181.29 after Guggenheim reiterated a Neutral rating, citing that the stock price has outpaced the company's actual business performance. Analysts point to weak customer demand, fewer job postings, and a cautious mid-m...
Thryv Holdings is selling its traditional print directory business for $142 million to focus on business automation software for small and medium businesses. CEO Walsh Joe bought 25,000 shares at $1.80 each, increasing his stake to 788,099 shares, si...
